Immunoregulation and antidepressant effect of ketamine
Major depressive disorder (MDD) is a common mental health disorder that brings severe disease burden worldwide. Traditional antidepressants are mainly targeted at monoamine neurotransmitters, with low remission rates and high recurrence rates. Ketamine is a noncompetitive glutamate N-methyl-d-aspart...
Guardado en:
Autores principales: | Zhang Nan, Yao Lihua, Wang Peilin, Liu Zhongchun |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
De Gruyter
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/24189d1466ac471dbf4a27d7aeea6650 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Novel Insights Into the Neurobiology of the Antidepressant Response From Ketamine Research: A Mini Review
por: Michael Colla, et al.
Publicado: (2021) -
Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency
por: Naghmeh Nikkheslat
Publicado: (2021) -
BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study
por: Huang XB, et al.
Publicado: (2020) -
An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression
por: Sherry-Anne Muscat, et al.
Publicado: (2021) -
Mania following ketamine abuse
por: Lu YY, et al.
Publicado: (2016)